“A pill that cuts off the supply of nutrients to tumors shows promise for treating people with the rare type of pancreatic cancer that afflicted Apple CEO Steve Jobs,” Charlene Laino reports for WebMD Health News.
“In a study of 171 people with advanced pancreatic neuroendocrine tumors, the drug, Sutent, doubled the length of time before their disease worsened,” Laino reports. “Cancer progressed in 5.5 months among patients on placebo vs. 11.4 months among patients on Sutent. Sutent also cut the risk of dying by 60%, says Eric Raymond, MD, head of medical oncology at the Hospital Beaujon in Clichy, France.”
“The findings were presented at the 2010 Gastrointestinal Cancers Symposium (GCS),” Laino reports. “‘For the first time in 18 years, [a new drug] has demonstrated benefit in these patients,’ Raymond tells WebMD.”
“‘Even though they are rare, these tumors are a life-limiting event for patients who have them. This is a very strong study,’ says Richard M. Goldberg, MD, head of the North Carolina Cancer Hospital in Chapel Hill,” Laino reports. “‘I am hopeful it will change how we treat these patients,’ says Goldberg, who was not involved with the research.”
“Pancreatic neuroendocrine tumors account for about 1% of all pancreatic cancers. An estimated 42,500 people were diagnosed with pancreatic cancer in 2009, according to the American Cancer Society,” Laino reports. “If diagnosed early, neuroendocrine tumors can often be surgically removed before they have spread throughout the body, experts say.”
Full article here.
[Thanks to MacDailyNews Reader “Lynn W.” for the heads up.]